ALX Oncology Holdings Inc. Common Stock
ALXOStock
$2.07+326.62%52W
Market Cap$273.16M
P/E—
Div yield—
Beta0.39
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)76.51%
Price vs S&P 500 (4W)26.98%
VGM Score72.35
Market Capitalization$273.16M
Earnings Surprise History
Q1 26-0.15est. -0.20
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.08
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALXOALX Oncology Holdings Inc. Common Stock | — | — | B | $2.07 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
ALX Oncology is a clinical-stage immuno-oncology company developing CD47-blocking therapies to enhance the immune system's ability to recognize and eliminate cancer cells. The company's lead program, evorpacept, is in phase 1 and 2 clinical trials and targets the CD47 "don't eat me" signal that allows cancer cells to evade immune detection. ALX's approach leverages protein engineering expertise to achieve high CD47 affinity while avoiding the hematologic toxicities that limit other CD47-blocking strategies.